Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday.

According to Zacks, “Conatus’ third-quarter results were encouraging with the company reporting a narrower-than-expected loss. The company’s progress with its lead candidate, emricasan, has been encouraging. Emricasan is in phase II development for the treatment of chronic liver disease, including NASH fibrosis under the ENCORE program. Conatus also plans to initiate studies on emricasan targeting different types of NASH patient populations. Given that there are currently no approved therapies for NASH and the significant market opportunity, the company’s efforts to develop emricasan are promising. Moreover, the company’s plans to evaluate partnership opportunities for emricasan outside North America could be rewarding, if successful. However, emricasan is still several years away from entering the market, if at all. Any development/regulatory setback could hamper the company’s prospects and impact the stock adversely.”

CNAT has been the subject of several other research reports. JMP Securities reissued a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Wednesday, November 9th. FBR & Co reissued an “outperform” rating and issued a $16.00 target price on shares of Conatus Pharmaceuticals in a research note on Tuesday, August 30th. Brean Capital reissued a “buy” rating and issued a $7.00 target price on shares of Conatus Pharmaceuticals in a research note on Tuesday, October 4th. Finally, Stifel Nicolaus cut their target price on shares of Conatus Pharmaceuticals from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Conatus Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $9.00.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) traded down 2.1295% on Monday, reaching $1.8889. 34,461 shares of the company’s stock traded hands. The stock’s 50-day moving average price is $1.86 and its 200-day moving average price is $2.03. The stock’s market capitalization is $47.55 million. Conatus Pharmaceuticals has a 52 week low of $1.40 and a 52 week high of $4.05.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.03. During the same period last year, the company posted ($0.31) EPS. Equities analysts predict that Conatus Pharmaceuticals will post ($1.28) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2016/11/28/zacks-investment-research-lowers-conatus-pharmaceuticals-inc-cnat-to-hold.html.

Hedge funds have recently bought and sold shares of the stock. D. E. Shaw & Co. Inc. boosted its stake in Conatus Pharmaceuticals by 94.5% in the third quarter. D. E. Shaw & Co. Inc. now owns 87,788 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 42,649 shares during the period. Courage Capital Management LLC acquired a new stake in Conatus Pharmaceuticals during the third quarter valued at approximately $200,000. KCG Holdings Inc. acquired a new stake in Conatus Pharmaceuticals during the third quarter valued at approximately $135,000. AXA boosted its stake in Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock valued at $2,237,000 after buying an additional 14,939 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock valued at $925,000 after buying an additional 15,300 shares during the period. Institutional investors own 15.97% of the company’s stock.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

5 Day Chart for NASDAQ:CNAT

Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.